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ABSTRACT
20-O-Aminooxymethyl ribonucleosides are prepared
from their 30,50-disilylated 20-O-phthalimidooxy-
methyl derivatives by treatment with NH4F in MeOH.
The reaction of these novel ribonucleosides with
1-pyrenecarboxaldehyde results in the efficient for-
mation of stable and yet reversible ribonucleoside
20-conjugates in yields of 69–82%. Indeed, exposure
of these conjugates to 0.5M tetra-n-butylammo-
nium fluoride (TBAF) in THF results in the cleavage
of their iminoether functions to give the native ribo-
nucleosides along with the innocuous nitrile side
product. Conversely, the reaction of 5-cholesten-
3-one or dansyl chloride with 20-O-aminooxymethyl
uridine provides permanent uridine 20-conjugates,
which are left essentially intact upon treatment with
TBAF. Alternatively, 50-O-aminooxymethyl thymidine
is prepared by hydrazinolysis of its 30-O-levulinyl-50-
O-phthalimidooxymethyl precursor. Pyrenylation of
50-O-aminooxymethyl thymidine and the sensitivity
of the 50-conjugate to TBAF further exemplify
the usefulness of this nucleoside for modifying
DNA sequences either permanently or reversibly.
Although the versatility and uniqueness of 20-O-
aminooxymethyl ribonucleosides in the preparation
of modified RNA sequences is demonstrated by
the single or double incorporation of a revers-
ible pyrenylated uridine 20-conjugate into an RNA
sequence, the conjugation of 20-O-aminooxymethyl
ribonucleosides with aldehydes, including those
generated from their acetals, provides reversible
20-O-protected ribonucleosides for potential appli-
cations in the solid-phase synthesis of native RNA
sequences. The synthesis of a chimeric polyuridylic
acid is presented as an exemplary model.
INTRODUCTION
Over the past decade, the 20-hydroxy function of ribo-
nucleosides has been extensively modiﬁed for the purpose
of identifying the biophysical and biochemical parameters
necessary for effective and lasting RNA interference-
mediated gene silencing activities (1–4). Actually,
20-hydroxy modiﬁcations are known to impart high bind-
ing afﬁnity to RNA sequences, increased lipophilicity,
enhanced chemical stability and resistance to nucleases
(1,2,5). The 20-hydroxyl group of ribonucleosides is also
an attractive function for conjugation reactions; there are
numerous examples of ribonucleoside 20-conjugates that
have been reported in various structural studies (6,7) as
well as in therapeutic and diagnostic applications (8,9).
Although 20-O-alkylation of ribonucleosides with func-
tional groups has often been employed in the synthesis
of ribonucleoside 20-conjugates (8,9), this method is gen-
erally lacking the regioselectivity needed for theproduction
of conjugates free of isomeric impurities. An alternate
strategytothepreparationofribonucleosides20-conjugates
is the use of the oxyamino-aldehyde coupling reaction
(10–12), which incidentally has extensively been applied
to the derivatization of oligonucleotides (13–20).
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coupling reaction has, to the best of our knowledge, never
been demonstrated, we rationalized that the conjugation
of 20-O-aminooxymethyl ribonucleosides with various
functional groups may provide a powerful tool for the
preparation and incorporation of permanent or reversible
ribonucleoside 20-conjugates into RNA sequences.
Furthermore, reversible ribonucleoside 20-conjugates may
especially be useful in identifying novel ribonucleoside
20-hydroxyl protecting groups, which have historically
been shown to be of critical importance in RNA synthe-
sis (21) and may lead to an improved approach to the
solid-phase synthesis of native or modiﬁed RNA se-
quences. Given that the preparation of 20-O-amino-
oxymethyl ribonucleosides has not been described in
the scientiﬁc literature, we are now reporting an efﬁcient
method for the synthesis of these ribonucleosides (5a–d,
Scheme 1) and that of several permanent or reversible
20-conjugates (Figure 1). With the objective of demonst-
rating the reversibility of 20-O-aminooxymethyl ribo-
nucleoside conjugates, the details of an unprecedented
ﬂuoride-mediated conversion of conjugates 6a–d, 12, 14,
16 and 18 to their native ribonucleosides (Scheme 2 and
Figure 2) will be discussed. Furthermore, 50-O-aminooxy-
methyl thymidine (25, Scheme 3) has also been prepared
for the ﬁrst time and the addition of its pyrenylated con-
jugate 26 to the 50-terminus of a DNA sequence serves as
a relevant example for the permanent or reversible
functionalization of DNA sequences at their 50-termini.
A single or a double incorporation of the 20-O-pyreny-
lated ribonucleoside conjugate 6a into a chemically syn-
thesized oligoribonucleotide (21-mer) is performed to
further substantiate the permanent/reversible properties
of the modiﬁed RNA sequence. Moreover, the phosphor-
amidite derivative of the reversible uridine 20-conjugate
29 (Scheme 4) is incorporated into a chimeric poly-
uridylic sequence (21-mer) in order to provide convincing
evidence of the usefulness and versatility of 20-O-
aminooxymethyl ribonucleoside conjugates in the design
and implementation of novel 20-hydroxyl protecting
groups for potential applications in the synthesis of
modiﬁed or native RNA sequences.
MATERIALS AND METHODS
30,50-O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-20-O-
(methylthiomethyl)uridine (2a)
The preparation of 2a was performed with minor modiﬁ-
cations of a published procedure (22,23). To a solution of
commercial 50-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)uridine (1a, 7.3g, 15mmol) in DMSO (15ml) was
added glacial AcOH (23ml) and Ac2O (15ml). The
solution was stirred at 50 C until completion of the reac-
tion (16h), which was monitored by TLC (CHCl3:MeOH
95:5 v/v). The solution was transferred to a 2l Erlenmeyer
ﬂask to which was added, under vigorous stirring, a
solution of K2CO3 (31g) in water (200ml). The precipi-
tated material was isolated either by ﬁltration or decanta-
tion and was redissolved in a minimum volume of THF
(15–20ml). The resulting solution was then poured into
water (250ml) to give the crude product as a gummy
material. Most of the water was decanted; the crude prod-
uct was carefully dried by consecutive coevaporation with
pyridine (30ml), toluene (3 30ml) and dichloromethane
(30ml). The crude ribonucleoside 2a was puriﬁed by chro-
matography on silica gel using a gradient of MeOH (0 !
3%) in CH2Cl2 as the eluent. Fractions containing pure 2a
were collected, evaporated to a foam under low pressure,
and dissolved in dry C6H6 ( 20ml); the solution was
Scheme 1. Synthesis of 20-O-pyrenylated ribonucleosides derivatives.
(i) DMSO, Ac2O, AcOH, 50 C, 16h; (ii) silica gel chromatography;
(iii) SO2Cl2,C H 2Cl2,2 5  C, 2h; (iv) N-hydroxyphthalimide, DBU,
CH2Cl2,2 5  C, 24h; (v) NH4F, MeOH, 25 C, 16h; (vi) concd aq
NH3,5 5  C, 1h; (vii) 1-pyrenecarboxaldehyde, MeOH, 55 C, 1h;
(viii) DMTrCl, pyridine, 25 C, 16h; (ix) 2-cyanoethyl N,N-diisopropyl-
chlorophosphoramidite, Et3N, CH2Cl2,2 5  C, 2h. Abreviations. B
P:
a, uracil-1-yl; b, N
4-acetylcytosin-1-yl; c, N
6-isobutyryladenin-9-yl; d,
N
2-phenoxyacetylguanin-9-yl; B: a, uracil-1-yl; b, cytosin-1-yl; c,
adenin-9-yl; d, guanin-9-yl; DMTr, 4,40-dimethoxytrityl.
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white powder (7.00g, 12.8mmol, 85%). Characterization
data obtained from
1H and
13C NMR analysis of 2a
are in agreement with those reported by Semenyuk
et al. (23).
30,50-O-(1,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)-20-O-
(phthalimidooxymethyl)uridine (4a)
To a solution of thoroughly dried 2a (1.1g, 2.0mmol) in
anhydrous CH2Cl2 (20ml) was added sulfuryl chloride
(176ml, 2.20mmol); the solution was stirred at  25 C
for 2h and was then concentrated under reduced pressure
to give the 20-O-chloromethyluridine derivative 3a as an
amorphous solid. N-Hydroxyphthalimide (1.3g, 8.0mmol)
was placed into a separate reaction vessel to which was
added anhydrous CH2Cl2 (10ml) and DBU (1.04ml,
7.00mmol). After 10min, the red solution was added to
unpuriﬁed 3a; the reaction mixture was kept stirring at
 25 C for 24h at which point CH2Cl2 (80ml) was
added. The solution was vigorously mixed with aqueous
1M acetic acid (20ml); the aqueous layer was discarded
and the organic phase was washed twice with a saturated
aqueous solution of NaHCO3 (20ml). The organic layer
was collected, dried over anhydrous Na2SO4, ﬁltered, and
evaporated to a foamy solid under reduced pressure. The
crude product 4a was puriﬁed by chromatography on
silica gel using a gradient of MeOH (0 ! 3%) in
CH2Cl2 as the eluent. Fractions containing 4a were col-
lected and evaporated under vacuum to give a solid
(1.24g, 1.88mmol) in a yield of 94% based on the molar
amount of starting material (2a) that was employed.
1H NMR (300MHz, DMSO-d6): d 11.41 (d, J=2.2Hz,
1H), 7.88-7.80 (m, 4H), 7.65 (d, J=8.2Hz, 1H), 5.62
(dd, J=8.2, 2.2Hz, 1H), 5.39 (d, J=7.2Hz, 1H), 5.34
(d, J=7.2Hz, 1H), 4.87 (d, J=5.2Hz, 1H), 4.63
(dd, J=5.2, 5.2Hz, 1H), 4.03 (dd, J=13.0, 3.0Hz,
1H), 3.90 (dd, J=13.0, 3.0Hz, 1H), 3.79 (dt, J=9.0,
3.0Hz, 1H), 1.07–0.95 (m, 28H).
13C NMR (75MHz,
DMSO-d6): d 163.2, 163.0, 150.0, 142.6, 134.8, 128.4,
123.3, 101.3, 98.0, 90.6, 80.2, 77.9, 69.8, 60.2, 17.2, 17.1,
17.0, 16.81, 16.77, 16.7, 12.5, 12.3, 12.1, 12.0. +ESI-
HRMS: Calcd for C30H43N3O10Si2 [M+H]
+ 662.2560,
found 662.2560.
20-O-(Aminooxymethyl)uridine (5a)
Puriﬁed 4a (330mg, 500mmol) was dissolved in methanol
(3ml), and ammonium ﬂuoride (185mg, 5.00mmol) was
added. The heterogenous reaction mixture was stirred at
 25 C until desilylation and dephthalimidation were
complete (16h) as indicated by TLC [CHCl3:MeOH
(9:1 v/v)]. The reaction product was puriﬁed by silica gel
chromatography using a gradient of MeOH (0 ! 12%) in
CH2Cl2 as the eluent. Fractions containing the product
were collected and evaporated to dryness under low
pressure to provide 5a.
1H NMR (300MHz, DMSO-d6):
d 11.4 (br s, 1H), 7.93 (d, J=8.1Hz, 1H), 6.21 (br s, 2H),
5.87 (d, J=4.4Hz, 1H), 5.64 (d, J=8.1Hz, 1H), 5.17
(t, J=4.9Hz, 1H), 4.74 (s, 2H), 4.11 (m, 2H), 3.88
(m, 1H), 3.65 (ddd, J=12.0, 5.0, 3.1Hz, 1H), 3.56 (ddd,
J=12.0, 5.0, 3.1Hz, 1H), 3.16 (d, J=5.0Hz, 1H).
13C
NMR (75MHz, DMSO-d6): d 163.1, 150.7, 140.4, 101.8,
98.0, 86.7, 84.9, 79.1, 69.0, 60.4.+ESI-HRMS: Calcd for
C10H15N3O7 [M+H]
+290.0983, found 290.0986.
20-O-(Pyren-1-ylmethanimine-N-oxymethyl)uridine (6a)
20-O-(Aminooxymethyl)uridine (5a) was prepared from 4a
at the scale and under conditions identical to those
described above. After complete NH4F-mediated desilyla-
tion and dephthalimidation, 1-pyrenecarboxaldehyde
(460mg, 2.00mmol) was added to the reaction mixture,
which was then heated at 55 C in a 4-ml screw-cap glass
vial until completion of the oximation reaction (1h) as
indicated by TLC [CHCl3:MeOH (9:1 v/v)]. The reaction
mixture was transferred to a 20-ml screw-cap glass vial to
which was added CH2Cl2 (7ml) and a saturated aqueous
solution of NaHCO3 (2ml); after vigorous shaking the
organic phase was collected and evaporated to dryness
under vacuum. The pyrenylated ribonucleoside 6a was
puriﬁed by chromatography on silica gel employing a
gradient of MeOH (0 ! 8%) in CH2Cl2 as the eluent.
Fractions containing the pure product were collected
and evaporated to dryness under reduced pressure afford-
ing 6a as a yellowish powder (206mg, 410mmol) in a yield
of 82% based on the molar amount of starting material
(4a) that was used.+ESI-HRMS: Calcd for C27H23N3O7
[M+H]
+ 502.1609, found 502.1609.
50-O-(4,40-dimethoxytrityl)-20-O-(pyren-1-ylmethanimine-
N-oxymethyl)uridine (7a)
To a solution of dry 6a (200mg, 400mmol) in anhydrous
pyridine (1ml) was added 4,4’-dimethoxytrityl chloride.
The solution was allowed to stir for 16h at  25 C
and was then evaporated to a gum under reduced pressure.
The material was dissolved in CHCl3 (10ml) and was
washed with a saturated aqueous solution of NaHCO3
(3ml). The organic layer was collected, dried over anhyd-
rous Na2SO4, ﬁltered and evaporated to a solid
under low pressure. The crude product 7a was puriﬁed
by chromatography on silica gel using a gradient of
MeOH (0 ! 2%) in CH2Cl2 containing 0.2% Et3Na s
the eluent. Fractions containing 7a were collected and
evaporated under vacuum to give a solid (293mg,
364mmol, 91%).
50-O-(4,40-dimethoxytrityl)-30-O-[(N,N-diisopropylamino)
(2-cyanoethyl)]phosphinyl-20-O-(pyren-1-ylmethanimine-
N-oxymethyl)uridine (8a)
To a solution of 7a (250mg, 311mmol) in anhydrous
CH2Cl2 (3ml) containing Et3N (167ml, 1.20mmol) was
added 2-cyanoethyl N,N-diisopropylchlorophosphor-
amidite(140ml,622mmol).Thereactionmixturewasstirred
at  25 C under argon until complete disappearance of 7a
was observed (2h) by TLC [C6H6:Et3N (9:1 v/v)]. The
reaction mixture was then poured into water (3ml) and
was extracted with CH2Cl2 (10ml). The organic layer was
dried over anhydrous Na2SO4 and then ﬁltered. The
ﬁltrate was evaporated to dryness under reduced pressure.
The crude phosphoramidite product was puriﬁed by chro-
matography on silica gel using C6H6:Et3N (9:1 v/v) as the
eluent. Fractions containing the pure product were pooled
2314 Nucleic Acids Research, 2012,Vol.40, No. 5together and evaporated to dryness under vacuum. The
material was dissolved in dry C6H6 (3ml) and the resulting
solution was added to cold ( 78 C) stirred hexane
(100ml). The pure ribonucleoside phosphoramidite pre-
cipitated immediately as a yellow solid. After careful
decantation of hexane, the solid was dissolved in dry
C6H6 (3ml); the solution was frozen and then lyophilized
under high vacuum. Et3N-free 8a was isolated as a yellow-
ish powder (275mg, 0.27mmol, 88%).
31P NMR
(121MHz, C6D6): d 151.9, 150.2. +ESI-HRMS: Calcd
for C57H58N5O10P (M+Na)
+1026.3813, found 1026.3796.
N
4-Acetyl-30,50-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)-20-O-(methylthiomethyl)cytidine (2b)
The preparation of 2b was performed with minor modiﬁca-
tions of a published procedure (22,23). To a solution of
commercial N
4-acetyl-50-O-(1,1,3,3-tetraisopropyldisiloxane-
1,3-diyl)cytidine (1b, 7.9g, 15mmol) in DMSO (15ml) was
added glacial AcOH (15ml) and Ac2O (10ml). The
solution was stirred at 50 C until completion of the reac-
tion (16h), which was monitored by TLC [CHCl3:MeOH
(95:5 v/v)]. The solution was transferred to a 2 l
Erlenmeyer ﬂask to which was added, under vigorous
stirring, a solution of K2CO3 (31.2g) in water (240ml).
The precipitated material was worked-up, puriﬁed and
processed under conditions identical to those employed
in the preparation of 2a. The ribonucleoside 2b was
isolated as a white solid (8.30g, 14.1mmol, 94%).
1H
NMR (300MHz, DMSO-d6): d 11.08 (s, 1H), 8.19 (d,
J=7.5Hz, 1H), 7.35 (d, J=7.5Hz, 1H), 5.77 (s, 1H),
5.14 (d, J=11.2Hz, 1H), 5.04 (d, J=11.2Hz, 1H), 4.44
(d, J=4.4Hz, 1H), 4.22 (m, 3H), 3.93 (dd, J=13.6,
1.9Hz, 1H), 2.16 (s, 3H), 2.14 (s, 3H), 1.08-0.95 (m,
28H).
13C NMR (75MHz, DMSO-d6): d 170.9, 162.6,
154.1, 143.1, 95.0, 88.9, 81.3, 77.0, 73.0, 67.0, 59.2, 24.2,
17.1, 17.0, 16.9, 16.8, 16.7, 16.5, 12.6, 12.4, 12.3, 12.2, 11.8.
+ESI-HRMS: Calcd for C25H45N3O7SSi2 [M+H]
+
580.2590, found 580.2597.
N
4-Acetyl-30,50-O-(1,1,3,3-tetraisopropyldisiloxane-
1,3-diyl)-20-O-(phthalimidooxymethyl) cytidine (4b)
The preparation and puriﬁcation of 4b were performed at
a scale and under conditions identical to those described
above for the preparation of 4a. The ribonucleoside 4b
was obtained as a solid (1.04g, 1.48mmol) in a yield of
74% based on the molar amount of starting material (2b)
that was utilized.
1H NMR (300MHz, DMSO-d6): d 10.98
(s, 1H), 8.10 (d, J=7.5Hz, 1H), 7.87–7.80 (m, 4H), 7.22
(d, J=7.5Hz, 1H), 5.76 (s, 1H), 5.52 (d, J=7.0Hz, 1H),
5.45 (d, J=7.0Hz, 1H), 4.70 (d, J=4.8Hz, 1H), 4.41
(dd, J=4.8, 4.8Hz, 1H), 4.15 (dd, J=12.9, 1.2Hz,
1H), 4.00–3.88 (m, 2H), 2.10 (s, 3H), 1.04–0.89
(m, 28H).
13C NMR (75MHz, DMSO-d6): d 171.0,
162.9, 162.7, 154.0, 145.2, 134.7, 134.2, 128.5, 123.2,
122.9, 98.1, 95.0, 90.1, 80.8, 79.3, 68.3, 59.7, 24.3, 17.2,
17.12, 17.09, 17.0, 16.8, 16.7, 16.6, 12.5, 12.3, 12.2, 11.9.
+ESI-HRMS: Calcd for C32H46N4O10Si2 [M+H]
+
703.2825, found 703.2825.
20-O-(Aminooxymethyl)cytidine (5b)
Silica gel-puriﬁed 4b (351mg, 500mmol) was dissolved in
methanol (3ml), and ammonium ﬂuoride (185mg,
5.00mmol) was added. The heterogenous reaction mixture
was stirred at  25 C until desilylation and dephthalimida-
tion were complete (16h) as indicated by TLC
[CHCl3:MeOH (9:1 v/v)]. A stream of air was used to
remove MeOH from the reaction mixture and was fol-
lowed by the addition of commercial concentrated aqueous
NH3 (3ml); the resulting solution was kept at 55 C for 1h
in a tightly closed 4-ml screw-cap glass vial. Excess
ammonia was removed under a stream of air; the material
left was puriﬁed by silica gel chromatography using a
gradient of MeOH (0 ! 25%) in CH2Cl2 as the eluent.
Fractions containing the product were collected and eva-
porated to dryness under low pressure to give 5b.
1H
NMR (300MHz, DMSO-d6): d 7.92 (d, J=7.4Hz, 1H),
7.26 (m, 2H), 5.83 (d, J=3.2Hz, 1H), 5.74 (d, J=7.4Hz,
1H), 5.15 (br s, 1H), 4.77 (q, J=7.2Hz, 2H), 4.04 (m,
2H), 3.84 (m, 2H), 3.70 (dd, J=12.2, 2.2Hz, 1H), 3.70
(dd, J=12.2, 2.7Hz, 1H).
13C NMR (75MHz, DMSO-
d6): d 165.6, 155.3, 140.9, 97.7, 94.0, 88.2, 83.9, 79.3, 68.3,
59.9. +ESI-HRMS: Calcd for C10H16N4O6 [M+H]
+
289.1143, found 289.1145.
20-O-(Pyren-1-ylmethanimine-N-oxymethyl)cytidine (6b)
20-O-(Aminooxymethyl)cytidine (5b) was prepared from
4b at a scale and under conditions identical to those
described above. After removal of excess ammonia, the
material left was suspended in MeOH (3ml), reacted
with 1-pyrenecarboxaldehyde and processed under condi-
tions identical to those employed for the preparation of
6a. The pyrenylated ribonucleoside was puriﬁed on silica
gel using chromatographic conditions identical to those
used for the puriﬁcation of 6a affording 6b as a yellow
powder (188mg, 375mmol) in a yield of 75 % based on the
molar amount of starting material (4b) that was utilized.
+ESI-HRMS: Calcd for C27H24N4O6 [M+H]
+ 501.1769,
found 501.1769.
N
6-Isobutyryl-30,50-O-(1,1,3,3-tetraisopropyldisiloxane-
1,3-diyl)-20-O-(methylthiomethyl) adenosine (2c)
The preparation of 2c was performed with minor modiﬁ-
cations of a published procedure (22,23). To a solution of
commercial N
6-isobutyryl-50-O-(1,1,3,3-tetraisopropyldisi-
loxane-1,3-diyl)adenosine (1c, 8.7g, 15mmol) in DMSO
(23ml) was added glacial AcOH (23ml) and Ac2O
(15ml). The solution was stirred at 50 C until completion
of the reaction (16h), which was monitored by TLC
[CHCl3:MeOH (95:5 v/v)]. The solution was transferred
to a 2 l Erlenmeyer ﬂask to which was added, under
vigorous stirring, a solution of K2CO3 (46.2g) in water
(230ml). The precipitated material was worked-up and
puriﬁed under conditions identical to those employed in
the preparation of 2a. The ribonucleoside 2c was isolated
as a white solid (8.5g, 13.3mmol, 89%).
1H NMR
(300MHz, DMSO-d6): d 10.69 (s, 1H), 8.56 (s, 1H), 8.49
(s, 1H), 6.11 (d, J=1Hz, 1H), 5.00 (dd, J=5.3, 5.2Hz,
1H), 4.97 (d, J=11.4Hz, 1H), 4.91 (d, J=11.4Hz, 1H),
Nucleic Acids Research,2012, Vol.40, No. 5 23154.89 (d, J=4.8Hz, 1H), 4.08 (dd, J=12.9, 2.5Hz, 1H),
4.02 (dt, J=9.0, 2.5, Hz, 1H), 3.93 (dd, J=12.9, 2.3Hz,
1H), 2.96 (sept, J=6.7Hz, 1H), 2.08 (s, 3H), 1.12 (d,
J=6.7Hz, 6H), 1.09-0.97 (m, 28H).
13C NMR
(75MHz, DMSO-d6): d 175.2, 151.4, 150.8, 149.9, 142.6,
124.1, 87.6, 80.8, 76.7, 73.7, 69.3, 59.9, 34.2, 19.1, 17.2,
17.1, 17.0, 16.9, 16.8, 16.7, 12.7, 12.6, 12.3, 12.1, 11.9.
+ESI-HRMS: Calcd for C28H49N5O6SSi2 [M+H]
+
640.3015, found 640.3016.
N
6-Isobutyryl-30,50-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)-20-O-(phthalimidooxymethyl) adenosine (4c)
The preparation and puriﬁcation of 4c were performed at
a scale and under conditions identical to those described
above for the preparation of 4a. The ribonucleoside 4c
was obtained as a solid (1.24 g, 1.64mmol) in a yield of
82% based on the molar amount of the starting material
(2c) that was used.
1H NMR (300MHz, DMSO-d6): d
10.72 (s, 1H), 8.59 (s, 1H), 8.45 (s, 1H), 7.84-7.74
(m, 4H), 6.06 (d, J=1.1Hz, 1H), 5.45 (d, J=7.5Hz,
1H), 5.37-5.30 (m, 3H), 4.04–3.89 (m, 3H), 2.97 (sept,
J=6.8Hz, 1H), 1.15 (d, J=6.8Hz, 3H), 1.14
(d, J=6.8Hz, 3H), 1.04–0.96 (m, 28H).
13C NMR
(75MHz, DMSO-d6): d 175.2, 163.0, 151.2, 150.9, 149.9,
144.3, 134.8, 134.2, 128.3, 124.3, 123.2, 122.9, 98.4, 87.7,
80.2, 77.8, 70.3, 59.9, 34.3, 19.2, 19.1, 17.1, 17.0, 16.9, 16.8,
16.7, 12.6, 12.3, 12.1. +ESI-HRMS: Calcd for
C35H50N6O9Si2 [M+H]
+ 755.3251, found 755.3250.
20-O-(Aminooxymethyl)adenosine (5c)
The preparation of 5c from 4c was performed at a scale
and under conditions identical to those used for the prep-
aration of 5b. After removal of excess ammonia under a
stream of air, 20-O-(aminooxymethyl)adenosine was puri-
ﬁed by silica gel chromatography employing a gradient of
MeOH (0 ! 10%) in CH2Cl2 as the eluent. Fractions
containing the product were collected and evaporated
to dryness under low pressure affording 5c.
1H NMR
(300MHz, DMSO-d6): d 8.38 (s, 1H), 8.13 (s, 1H), 7.37
(br s, 2H), 6.21 (br s, 2H), 6.06 (d, J=6.0Hz, 1H), 5.43
(m, 2H), 4.68 (q, J=7.3Hz, 2H), 4.67 (m, 1H), 4.33 (br s,
1H), 3.99 (q, J=3.4Hz, 1H), 3.68 (m, 1H), 3.57 (m, 1H).
13C NMR (75MHz, DMSO-d6): d 156.1, 152.4, 148.9,
139.7, 119.2, 98.2, 86.3, 86.1, 79.3, 69.8, 61.4.
+ESI-HRMS: Calcd for C11H16N6O5 [M+H]
+ 313.1255,
found 313.1256.
20-O-(Pyren-1-ylmethanimine-N-oxymethyl)adenosine (6c)
The preparation of 5c from 4c was performed at a scale
and under conditions identical to those described above.
After removal of excess ammonia, the material left was
suspended in MeOH (3ml), reacted with 1-pyrenecarbox-
aldehyde and processed under conditions identical to
those employed for the preparation of 6a. The pyrenylated
ribonucleoside was puriﬁed on silica gel using chromato-
graphic conditions identical to those used for the puriﬁca-
tion of 6a affording 6c in a yield of 77% (200mg,
385mmol) based on the molar amount of starting material
(4c) that was employed. +ESI-HRMS: Calcd for
C28H24N6O5 [M+H]
+ 525.1881, found 525.1882.
N
2-Phenoxyacetyl-30,50-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-20-O-(methylthiomethyl)
guanosine (2d)
The preparation of 2d was performed with minor modiﬁ-
cations of a published procedure (22,23). To a solution of
commercial N
2-phenoxyacetyl-50-O-(1,1,3,3-tetraisopro-
pyldisiloxane-1,3-diyl)guanosine (1d, 9.9g, 15mmol) in
DMSO (22.5ml) was added glacial AcOH (22.5ml) and
Ac2O (15.0ml). The solution was stirred at 50 C until
completion of the reaction ( 16h), which was monitored
by TLC [CHCl3:MeOH (95:5 v/v)]. The solution was trans-
ferred to a 2 l Erlenmeyer ﬂask to which was added, under
vigorous stirring, a solution of K2CO3 (51.0g) in water
(270ml). The precipitated material was worked-up and
puriﬁed under conditions identical to those employed in
the preparation of 2a. The ribonucleoside 2d was isolated
as a white solid (9.3g, 13mmol, 87 %).
1H NMR
(300MHz, DMSO-d6): d 11.84 (br s, 1H), 11.83 (br s,
1H), 8.05 (s, 1H), 7.32 (d, J=7.6 Hz, 1H), 7.30 (d,
J=8.4Hz, 1H), 6.98 (m, 3H), 5.91 (d, J=1.1Hz, 1H),
4.95 (s, 2H), 4.84 (s, 2H), 4.52 (m, 2H), 4.16 (dd, J=12.9,
2.5Hz, 1H), 4.06 (dt, J=8.2, 2.5Hz, 1H), 3.95 (dd,
J=12.9, 2.5Hz, 1H), 2.08 (s, 3H), 1.06–0.95 (m, 28H).
13C NMR (75MHz, DMSO-d6): d 170.7, 157.5, 154.8,
147.6, 147.3, 136.1, 129.4, 121.3, 120.5, 114.5, 86.5, 81.3,
77.8, 73.8, 68.8, 66.2, 60.0, 17.2, 17.16, 17.13, 17.1, 17.05,
17.03, 16.8, 16.74, 16.70, 12.8, 12.7, 12.6, 12.3, 12.2, 11.9.
+ESI-HRMS: Calcd for C32H49N5O8SSi2 [M+H]
+
720.2913, found 720.2918.
N
2-Phenoxyacetyl-3’,5’-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-2’-O-
(phthalimidooxymethyl)guanosine (4d)
The preparation and puriﬁcation of 4d were performed at
a scale and under conditions identical to those described
above for the preparation of 4a. The ribonucleoside 4d
was obtained as a solid (1.10g, 1.32mmol) in a yield of
66% based on the molar amount of starting material (2d)
that was employed.
1H NMR (300MHz, DMSO-d6): d
11.81 (br s, 1H), 11.55 (br s, 1H), 8.15 (s, 1H), 7.85–7.70
(m, 4H), 7.34–7.28 (m, 3H), 6.99–6.94 (m, 3H), 5.94 (d,
J=1.3Hz, 1H), 5.48 (d, J=7.0Hz, 1H), 5.39 (d,
J=7.0Hz, 1H), 5.48 (dd, J=5.2, 1.2Hz, 1H), 4.75 (m,
2H), 4.64 (m, 1H), 4.07–3.89 (m, 3H), 1.07–0.95 (m, 28H).
13C NMR (75MHz, DMSO-d6): d 170.5, 162.9, 157.5,
154.9, 148.1, 147.2, 137.2, 134.8, 129.5, 128.3, 123.2,
121.3, 114.5, 98.4, 86.0, 80.7, 78.6, 70.2, 66.2, 60.1, 17.2,
17.1, 16.9, 16.8, 12.8, 12.6, 12.3, 12.05, 12.02. +ESI-
HRMS: Calcd for C39H50N6O11Si2 [M+H]
+ 835.3149,
found 835.3148.
20-O-(Aminooxymethyl)guanosine (5d)
The preparation of 5d from 4d was performed under con-
ditions identical to those used for the preparation of 5b.
After removal of excess ammonia under a stream of air, 20-
O-(aminooxymethyl)guanosine was puriﬁed by silica gel
chromatography using a gradient of MeOH (0 ! 25%)
in CH2Cl2 as the eluent. Fractions containing the product
were collected and evaporated to dryness under reduced
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1H NMR (300MHz, DMSO-d6): d
10.77 (br s, 1H), 7.96 (s, 1H), 6.59 (br s, 2H), 5.85 (d,
J=6.0Hz, 1H), 5.12 (t, J=5.2Hz, 1H), 4.72 (m, 2H),
4.46 (dd, J=6.0, 5.7Hz, 1H), 4.26 (dd, J=4.8, 4.8Hz,
1H), 3.91 (q, J=3.8Hz, 1H), 3.61 (dt, J=11.8, 4.4Hz,
1H), 3.52 (dt, J=11.8, 4.4Hz, 1H).
13C NMR
(75MHz, DMSO-d6): d 156.6, 153.8, 151.1, 135.3, 116.5,
98.0, 85.6, 84.8, 79.6, 69.6, 61.1.+ESI-HRMS: Calcd for
C11H16N6O6 [M+H]
+ 329.1204, found 329.1211.
20-O-(Pyren-1-ylmethanimine-N-oxymethyl)guanosine (6d)
The preparation of 5d from 4d was performed at a scale
and under conditions identical to those described above.
After removal of excess ammonia, the material left was
suspended in MeOH (3ml), reacted with 1-pyrenecarbox-
aldehyde and processed under conditions identical to
those employed for the preparation of 6a. The pyrenylated
ribonucleoside was puriﬁed on silica gel using chromato-
graphic conditions identical to those used for the puriﬁca-
tion of 6a affording 6d in a yield of 69% (187mg,
345mmol) based on the molar amount of starting
material (4d) that was utilized. +ESI-HRMS: Calcd for
C28H24N6O6 [M+H]
+ 541.1830, found 541.1829.
20-O-(5-Cholesten-3-imine-N-oxymethyl)uridine (10)
20-O-(Aminooxymethyl)uridine (5a) was prepared as de-
scribed above from silica gel-puriﬁed 4a (132mg,
200mmol). After complete NH4F-mediated desilylation
and dephthalimidation of 4a, 5-cholesten-3-one (9,
154mg, 400mmol) was added to the reaction mixture,
which was then processed under conditions identical to
those described in the preparation of 6a. The reaction
product was puriﬁed by chromatography on silica gel
using a gradient of MeOH (0 ! 4%) in CH2Cl2 as the
eluent. Fractions containing the pure product were col-
lected and evaporated to dryness under reduced pressure
giving 10 as a white powder (90mg, 0.14mmol) in a yield
of 69% based on the molar amount of starting material
(4a) that was used.+ESI-HRMS: Calcd for C37H57N3O7
[M+H]
+ 656.4269, found 656.4269. The normal phase
HPLC proﬁle of 10 is shown in Supplementary Figure S1.
N-(2,2-Dimethoxyethyl)biotinamide (11)
To a suspension of D-(+)-biotin 2-nitrophenyl ester
(365mg, 1.00mmol) in MeCN (20ml) was added
aminoacetaldehyde dimethyl acetal (130ml, 1.20mmol)
and Et3N (170ml, 1.20mmol). The suspension was gently
heated until a solution was obtained; the solution was then
stirred for 16h at  25 C. The reaction mixture was
evaporated to dryness under reduced pressure and the
material left was puriﬁed by silica gel chromatography
using a gradient of MeOH (0 ! 10%) in CH2Cl2 as the
eluent. Fractions containing the product were collected
and evaporated to dryness under low pressure affording
11 as a solid (300mg, 910mmol, 91%).
1H NMR
(300MHz, DMSO-d6): d 7.87 (t, J=5.8Hz, 1H), 6.43
(s, 1H), 6.37 (s, 1H), 4.32 (t, J=5.5Hz, 1H), 4.28 (d,
J=5.5Hz, 1H), 4.12 (ddd, J=7.6, 4.4, 1.8Hz, 1H),
3.25 (s, 6H), 3.13 (t, J=5.7Hz, 2H), 2.82 (dd, J=12.3,
12.3Hz, 1H), 2.56 (d, J=12.3Hz, 1H), 2.07 (t,
J=7.4Hz, 2H), 1.66-1.22 (m, 7H).
13C NMR (75MHz,
DMSO-d6): d 172.2, 162.6, 102.0, 61.0, 59.1, 55.4, 53.1,
40.2, 39.8, 34.9, 28.1, 28.0, 25.2.+ESI-HRMS: Calcd for
C14H25N3O4S [M+H]
+ 332.1639, found 332.1641.
N-(2-Oxoethyl)biotinamide
The acetal 11 (280mg, 850mmol) was dissolved in MeOH
(2ml) and commercial concentrated HCl (0.5ml) was
added to the solution, which was allowed to stir for 1h
at  25 C. The reaction mixture was evaporated to dryness
under reduced pressure to yield the aldehyde, the total
amount of which was used without further puriﬁcation
in the preparation of 12.
Preparation of the biotinylated uridine conjugate 12
20-O-(Aminooxymethyl)uridine (5a) was prepared from
silica gel-puriﬁed 4a at a scale and under conditions iden-
tical to those described for the preparation of 10. After
complete NH4F-mediated desilylation and dephthalimida-
tion, all of the N-(2-oxoethyl)biotinamide produced above
was dissolved in MeOH (2ml) and added to the reaction
mixture, which was heated at 55 C in a 4-ml screw-cap
glass vial until completion of the oximation reaction (1h)
as indicated by TLC [CHCl3:MeOH (9:1 v/v)]. The
reaction mixture was puriﬁed by chromatography on
silica gel employing a gradient of MeOH (0 ! 20%) in
CH2Cl2 as the eluent. Fractions containing the pure
product were collected and evaporated to dryness under
reduced pressure providing 12 as a white powder (74mg,
0.13mmol) in a yield of 66% based on the molar amount
of starting material (4a) that was utilized. +ESI-HRMS:
Calcd for C22H32N6O9S [M+H]
+ 557.2024, found
557.2024. The RP-HPLC proﬁle of 12 is shown in
Supplementary Figure S2A.
N-(2,2-Dimethoxyethyl)-5-(dimethylamino)naphthalene-1-
sulfonamide (13)
To a solution of dansyl chloride (270mg, 1.00mmol) in
CH2Cl2 (10ml) was added aminoacetaldehyde dimethyl
acetal (130ml, 1.20mmol) and Et3N (170ml, 1.20mmol);
the solution was allowed to stir for 1h at  25 C.
The reaction mixture was then evaporated to dryness
under vacuum and the material left was puriﬁed by silica
gel chromatography using a gradient of MeOH (0 ! 1%)
in CH2Cl2 as the eluent. Fractions containing the product
were collected and evaporated to dryness under low pres-
sure affording 13 as a solid (318mg, 940mmol, 94%).
1H NMR (300MHz, DMSO-d6): d 8.45 (dt, J=8.5, 1.1
Hz, 1H), 8.29 (dt, J=8.8, 0.9Hz, 1H), 8.16 (t, J=5.5Hz,
1H), 8.10 (dd, J=7.3, 1.1Hz, 1H), 7.61 (t, J=8.5Hz,
1H), 7.58 (t, J=8.5Hz, 1H), 7.25 (dd, J=7.6, 0.7Hz,
1H), 4.11 (t, J=5.5Hz, 1H), 3.06 (s, 6H), 2.89
(t, J=5.5Hz, 2H), 2.81 (s, 6H).
13C NMR (75MHz,
DMSO-d6): d 151.2, 136.2, 129.3, 128.9, 127.9, 127.7,
123.5, 119.1, 115.0, 102.4, 53.3, 44.9, 43.9.+ESI-HRMS:
Calcd for C16H22N2O4S [M+H]
+ 339.1373, found
339.1374.
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The acetal 13 (287mg, 850mmol) was dissolved in MeOH
(1ml) and concentrated HCl (0.5ml) was added to the so-
lution, which was stirred for 1h at  25 C. The reaction
mixture was then evaporated to dryness under reduced
pressure; the material left was dissolved in CH2Cl2
(10ml) and the solution was washed with NaHCO3 (2ml
of a saturated aqueous solution). The organic layer was
collected and was evaporated under low pressure to give
the aldehyde as a pale green foam, the total amount of
which was used without further puriﬁcation in the prep-
aration of 14.
Preparation of the dansylated uridine conjugate 14
20-O-(Aminooxymethyl)uridine (5a) was prepared from
silica gel-puriﬁed 4a at a scale and under conditions iden-
tical to those described for the preparation of 10. After
complete NH4F-mediated desilylation and dephthalimida-
tion, all of the N-(2-oxoethyl)-5-(dimethylamino)
naphthalene-1-sulfonamide generated above was dissolved
in MeOH (1ml) and added to the reaction mixture, which
was heated at 55 C in a 4-ml screw-cap glass vial until
completion of the oximation reaction (1h) as indicated
by TLC [CHCl3:MeOH (9:1 v/v)]. The reaction mixture
was then worked-up and processed exactly as described in
the preparation of 10. The product was puriﬁed by chro-
matography on silica gel employing a gradient of MeOH
(0 ! 6%) in CH2Cl2 as the eluent. Fractions containing
the pure product were collected and evaporated to dryness
under reduced pressure to give 14 as a pale green powder
(82mg, 0.14mmol) in a yield of 70 % based on the molar
amount of starting material (4a) that was employed.
+ESI-HRMS: Calcd for C24H29N5O9S [M+H]
+
564.1759, found 564.1759. The RP-HPLC proﬁle of 14 is
shown in Supplementary Figure S3A.
N-(4,4-Diethoxybutyl)-5-(dimethylamino)naphthalene-1-
sulfonamide (15)
To a solution of dansyl chloride (270mg, 1.00mmol) in
CH2Cl2 (10ml) was added 4-aminobutyraldehyde diethyl
acetal (237ml, 1.20mmol) and Et3N (170ml, 1.20mmol).
The solution was stirred for 1h at  25 C and was then
evaporated to dryness under low pressure. The material
left was processed and puriﬁed under conditions identical
to those described for the processing and puriﬁcation of
13. Fractions containing the product were collected and
evaporated to dryness under low pressure affording 15 as
a solid (366mg, 930mmol, 93%).
1H NMR (300MHz,
DMSO-d6): d 8.45 (dt, J=8.5, 1.1Hz, 1H), 8.30 (dt,
J=8.8, 0.9Hz, 1H), 8.09 (dd, J=7.3, 1.2Hz, 1H), 7.89
(t, J=5.5Hz, 1H), 7.61 (t, J=8.5Hz, 1H), 7.58
(t, J=8.5Hz, 1H), 7.25 (dd, J=7.6, 0.7Hz, 1H), 4.19
(t, J=5.3Hz, 1H), 3.36 (m, 2H), 3.23 (m, 2H), 2.81 (s,
6H), 2.77 (t, J=5.5Hz, 2H), 1.31 (m, 4H), 0.99 (t,
J=7.0Hz, 6H).
13C NMR (75MHz, DMSO-d6): d
151.2, 136.1, 129.2, 128.9, 128.1, 127.7, 123.5, 119.1,
114.9, 101.6, 60.2, 44.9, 42.2, 30.1, 24.4, 15.1.
+ESI-HRMS: Calcd for C20H30N2O4S [M+H]
+
395.1999, found 395.2000.
N-(4-Oxobutyl)-5-(dimethylamino)naphthalene-1-
sulfonamide
This aldehyde was prepared from acetal 15 at a scale and
under conditions identical to those employed for the
preparation N-(2-oxoethyl)-5-(dimethylamino)naphthalene-
1-sulfonamide from acetal 13. N-(4-Oxobutyl)-5-(dimethyla-
mino)naphthalene-1-sulfonamide was obtained as a pale
green foam, the total amount of which was used without
further puriﬁcation in the preparation of 16.
Preparation of the dansylated uridine conjugate 16
This conjugate was prepared and puriﬁed exactly as re-
ported for the preparation and puriﬁcation of the
dansylated uridine conjugate 14. The dansylated uridine
conjugate 16 was isolated as a light green powder (96mg,
0.16mmol) in a yield of 81 % based on the molar amount
of starting material (4a) that was used. +ESI-HRMS:
Calcd for C26H33N5O9S [M+H]
+ 592.2072, found
592.2071. The RP-HPLC proﬁle of 16 is shown in
Supplementary Figure S4A.
N-(2,2-Dimethoxyethyl)-4-(dimethylamino)azobenzene-40-
sulfonamide (17)
To a solution of 4-(dimethylamino)azobenzene-40-sulfonyl
chloride (324mg, 1.00mmol) in CH2Cl2 (5ml) was added
aminoacetaldehyde dimethyl acetal (130ml, 1.20mmol)
and Et3N (179ml, 1.20mmol). The solution was allowed
to stir for 16h at  25 C. The reaction mixture was
evaporated to dryness under reduced pressure and the
material left was puriﬁed by silica gel chromatography
using a gradient of MeOH (0 ! 2%) in CH2Cl2 as the
eluent. Fractions containing the product were collected
and evaporated to dryness under reduced pressure afford-
ing 17 as a solid (373mg, 950mmol, 95%).
1H NMR
(300MHz, DMSO-d6): d 7.82 (d, J=9.3Hz, 2H), 7.19
(m, 4H), 6.85 (d, J=9.3Hz, 2H), 4.29 (t, J=5.4Hz,
1H), 3.19 (s, 6H), 3.08 (s, 6H), 2.89 (t, J=5.6Hz, 2H).
13C NMR (75MHz, DMSO-d6): d 154.4, 153.0, 142.5,
140.5, 127.7, 125.3, 122.1, 111.5, 102.3, 53.3, 44.1, 39.8.
+ESI-HRMS: Calcd for C18H24N4O4S [M+H]
+393 1591,
found 393.1596.
N-(2-Oxoethyl)-4-(dimethylamino)azobenzene-40-
sulfonamide
The acetal 17 (287mg, 850mmol) was dissolved in a
solution of 10% (w/v) I2 in acetone (10ml) (24). The re-
sulting solution was stirred at  25 C for 16h and was
then evaporated to dryness under reduced pressure. The
material left was dissolved in CH2Cl2 (10ml) and washed
with an aqueous solution of 5% (w/v) sodium bisulﬁte
(5ml) followed by a saturated aqueous solution of
NaHCO3 (5ml). The organic layer was collected and
was evaporated to dryness under vacuum. The total
amount of the orange product was used in the preparation
of 18.
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20-O-(Aminooxymethyl)cytidine (5b) was prepared from
silica gel-puriﬁed 4b (140mg, 0.2mmol) as described
above. After removal of excess ammonia, the material
left was suspended in MeOH (3ml) and all of the N-(2-
oxoethyl)-4-(dimethylamino)azobenzene-40-sulfonamide
produced above was suspended in MeOH (1ml)
and added to the reaction mixture, which was heated at
55 C in a 4-ml screw-cap glass vial until completion of
the oximation reaction (1h) as indicated by TLC
[CHCl3:MeOH (9:1 v/v)]. The reaction mixture was
then worked-up and processed exactly as described in
the preparation of 10. The product was puriﬁed by chro-
matography on silica gel employing a gradient of MeOH
(0 ! 8%) in CH2Cl2 as the eluent. Fractions containing
the pure product were collected and evaporated to dryness
under reduced pressure providing 18 as an orange powder
(74mg, 0.12mmol) in a yield of 61% based on the molar
amount of starting material (4b) that was employed.
+ESI-HRMS: Calcd for C26H32N8O8S [M+H]
+
617.2137, found 617.2134. The RP-HPLC proﬁle of 18 is
shown in Supplementary Figure S5A.
N-(4-Cyanobut-1-yl)-5-(dimethylamino)naphthalene-1-
sulfonamide (20)
4-Aminobutyronitrile was prepared from the reaction of
4-chlorobutyronitrile (207mg, 2.00mmol) with potassium
phthalimide (407mg, 2.20mmol) under the conditions
described by McKay et al. (25) with the following modi-
ﬁcation: the crude 4-aminobutyronitrile, instead of puriﬁed
4-aminobutyronitrile hydrochloride, was reacted with a
stirred solution of dansyl chloride (135mg, 500mmol) in
CH2Cl2 (1ml) for 10min at  25 C. The reaction product
was analyzed by TLC [CHCl3:MeOH (95:5 v/v)] and was
puriﬁed by chromatography on silica gel using a gradient
of MeOH (0 ! 3%) in CH2Cl2 as the eluent. Fractions
containing 20 were collected and evaporated under
vacuum affording the pure product (123mg, 390mmol)
in a yield of 78% based on the molar amount of dansyl
chloride used in the reaction.
1H NMR (300MHz,
DMSO-d6): d 8.47 (dt, J=8.5, 1.1Hz, 1H), 8.28 (dt,
J=8.5, 1.1Hz, 1H), 8.11 (dd, J=7.2, 1.2Hz, 1H), 8.02
(t, J=5.8Hz, 1H), 7.63 (t, J=7.5Hz, 1H), 7.60
(t, J=7.5Hz, 1H), 7.26 (dd, J=7.5, 0.7Hz, 1H), 2.85
(m, 2H), 2.82 (s, 6H), 2.39 (t, J=7.0Hz, 2H), 1.60
(quint, J=7.0Hz, 2H).
13C NMR (75MHz, DMSO-d6):
d 151.3, 135.5, 129.5, 129.0, 128.9, 128.3, 127.8, 123.5,
119.9, 118.8, 115.1, 44.9, 40.9, 25.2, 13.4. +ESI-HRMS:
Calcd for C16H19N3O2S [M+H]
+ 318.1271, found
318.1271.
20-O-[5-(Dimethylamino)naphthalene-1-sulfonamidyl-N-
oxymethyl]uridine (22)
Silica gel-puriﬁed 20-O-(aminooxymethyl)uridine (5a,
87mg, 0.30mmol) was dissolved in pyridine (2ml) and
dansyl chloride (135mg, 500mmol) was added. The
solution was stirred at  25 C for 2h and was then
evaporated to dryness under vacuum. The crude product
22 was puriﬁed by silica gel chromatography using a
gradient of MeOH (0 ! 8%) in CH2Cl2 as the eluent.
Fractions containing 22 were collected and evaporated
under vacuum giving a yellow solid (130mg, 250mmol,
83%). +ESI-HRMS: Calcd for C22H26N4O9S [M+H]
+
523.1493, found 523.1493. The RP-HPLC proﬁle of 22 is
shown in Supplementary Figure S6A.
30-O-(Levulinyl)-50-O-(methylthiomethyl)-20-
deoxythymidine (23)
To a solution of commercial 30-O-(levulinyl)-20-deoxy-
thymidine (3.0g, 8.8mmol) in DMSO (9ml) was added
glacial AcOH (13ml) and Ac2O (9ml). The solution was
stirred at  50 C until completion of the reaction (16h),
which was monitored by TLC [CHCl3:MeOH (95:5 v/v)].
AcOH and Ac2O were evaporated under vacuum and the
remaining material was mixed with 15g of silica gel.
Residual DMSO was allowed to evaporate from the
silica gel over a period of 16h at room temperature. The
silica gel mix was layered on the top of a glass column
packed with silica gel. The product was eluted using a
gradient of MeOH (0 ! 3%) in CH2Cl2 as the eluent.
Fractions containing pure 23 were collected, evaporated
to a foam under low pressure, and dissolved in dry C6H6
( 20ml); the solution was frozen and then lyophilized
under high vacuum affording a white powder (2.8g,
7.0mmol, 80%).
1H NMR (300MHz, DMSO-d6): d.
11.33 (s, 1H), 7.55 (s, 1H), 6.19 (t, J=6.2Hz, 1H), 5.18
(d, J=5.6Hz, 1H), 4.74 (s, 2H), 4.11 (s, 1H), 3.69 (s, 2H),
3.31 (s, 1H), 2.74 (t, J=6.2Hz, 2H), 2.50 (t, J=6.2Hz,
2H), 2.27 (m, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 1.79 (s, 3H).
13C NMR (75MHz, DMSO-d6): d 206.7, 171.9, 163.5,
150.3, 135.4, 109.8, 83.7, 82.2, 74.8, 74.7, 67.6, 37.3,
35.9, 29.4, 27.6, 13.4, 12.6. +ESI-HRMS: Calcd for
C17H24N2O7S [M+H]
+ 401.1377, found 401.1379.
30-O-(Levulinyl)-50-O-(phthalimidooxymethyl)-20-
deoxythymidine (24)
To a solution of thoroughly dried 23 (2.8g, 7.0mmol) in
anhydrous CH2Cl2 (70ml) was added neat sulfuryl
chloride (626ml, 7.73mmol); the solution was stirred at
 25 C for 2h and was then concentrated under reduced
pressure to give 50-O-chloromethyl-30-O-levulinyl-20-O-
deoxythymidine as an amorphous solid. N-
Hydroxyphthalimide (4.58g, 28.1mmol) was placed into
a separate reaction vessel to which was added anhydrous
CH2Cl2 (35ml) and DBU (3.60ml, 24.6mmol). After
10min, the red solution was added to unpuriﬁed 50-O-
chloromethyl-30-O-levulinyl-20-O-deoxythymidine; the re-
action mixture was kept stirring at  25 C for 24h at
which point CH2Cl2 (150ml) was added. The solution
was extracted twice with aqueous 1M acetic acid
(30ml); the organic phase was collected, washed with a
saturated aqueous solution of NaHCO3 (3 100ml),
dried over anhydrous Na2SO4, ﬁltered, and evaporated
to a foamy solid under reduced pressure. The crude prod-
uct was puriﬁed by chromatography on silica gel using a
gradient of MeOH (0 !3%) in CH2Cl2 as the eluent.
Fractions containing 24 were collected and evaporated
under vacuum to give a solid (2.1g, 4.1mmol, 58%).
1H
NMR (300MHz, DMSO-d6): d 11.31 (s, 1H), 7.87 (s, 4H),
Nucleic Acids Research,2012, Vol.40, No. 5 23197.48 (s, 1H), 6.17 (dd, J=6.0, 2.5Hz, 1H), 5.24 (m, 3H),
4.13 (m, 3H), 2.75 (t, J=6.2Hz, 2H), 2.50 (m, 2H), 2.25
(m, 2H), 2.12 (s, 3H), 1.64 (s, 3H).
13C NMR (75MHz,
DMSO-d6): d 206.7, 171.8, 163.4, 163.1, 150.3, 135.6,
134.8, 128.4, 123.2, 109.6, 100.0, 83.7, 81.8, 74.3, 69.3,
37.3, 35.6, 29.4, 27.6, 11.9.+ESI-HRMS: Calcd for
C24H25N3O10 [M+H]
+ 516.1613, found 516.1618.
50-O-(Aminooxymethyl)-20-deoxythymidine (25)
Under an inert atmosphere, 1M hydrazine hydrate in
pyridine:acetic acid (3:2 v/v, 7.3ml) was added to a
solution of 24 (1.2g, 2.3mmol) in anhydrous pyridine
(11ml). The reaction mixture was stirred for 1h at 25 C
and was then concentrated under vacuum to a volume of
 3ml. The crude product was puriﬁed by chromatog-
raphy on silica gel using a gradient of MeOH (0 !3%)
in CH2Cl2 as the eluent. Fractions containing 25 were col-
lected and evaporated under vacuum to give a solid
(318mg, 1.11mmol, 48%).
1H NMR (300MHz, DMSO-
d6): d 11.27 (br s, 1H), 7.61 (s, 1H), 6.19 (dd, J=6.5,
2.5Hz, 1H), 5.30 (br s, 2H), 4.70 (s, 2H), 4.26 (br s,
1H), 3.90 (br s, 1H), 3.71 (m, 3H), 2.12 (m, 2H), 1.78 (s,
3H).
13C NMR (75MHz, DMSO-d6): d 163.6, 150.3,
135.9, 109.4, 98.5, 85.2, 83.8, 70.6, 67.7, 39.0, 12.1.
+ESI-HRMS: Calcd for C11H17N3O6 [M+H]
+ 288.1190,
found 288.1196.
50-O-(Pyren-1-ylmethanimine-N-oxymethyl)-20-
deoxythymidine (26)
A solution of 25 (300mg, 1.05mmol) and 1-pyrenecarbox-
aldehyde (1.1g, 5.0mmol) in MeOH (2ml) was heated
at 55 C in a 4-ml screw-cap glass vial until completion
of the oximation reaction (1h) as indicated by TLC
[CHCl3:MeOH (9:1 v/v)]. The reaction mixture was trans-
ferred to a 20-ml screw-cap glass vial to which was added
CH2Cl2 (7ml) and a saturated aqueous solution of
NaHCO3 (2ml); after vigorous shaking the organic
phase was collected and evaporated to dryness under
vacuum. The pyrenylated product was puriﬁed by chro-
matography on silica gel employing a gradient of MeOH
(0 ! 5%) in CH2Cl2 as the eluent. Fractions containing
the pure product were collected and evaporated to dryness
under reduced pressure affording 26 as a yellowish powder
(400mg, 800mmol, 80%). +ESI-HRMS: Calcd for
C28H25N3O6 [M+Na]
+ 522.1636, found 522.1642.
50-O-(Pyren-1-ylmethanimine-N-oxymethyl)-3’-O-[(N,N-
diisopropylamino) (2-cyanoethyl)]phosphinyl-20-
deoxythymidine (27)
To a solution of 50-O-(pyren-1-ylmethanimine-N-
oxymethyl)-20-deoxythymidine (26, 350mg, 700mmol) in
anhydrous CH2Cl2 (5ml), containing Et3N (0.39ml,
2.8mmol), was added 2-cyanoethyl N,N-diisopropylchlor-
ophosphoramidite (0.31ml, 1.4mmol). The reaction
mixture was stirred at  25 C under argon until complete
disappearance of 26 (2h) was conﬁrmed by TLC
[C6H6:Et3N (9:1 v/v)]. The reaction mixture was then
poured into water (5ml) and was extracted with CH2Cl2
(15ml). The organic layer was dried over anhydrous
Na2SO4, ﬁltered and evaporated to dryness under reduced
pressure. The crude phosphoramidite product was puriﬁed
by chromatography on silica gel using C6H6:Et3N (9:1 v/v)
as the eluent. Fractions containing the pure product were
pooled together and evaporated to dryness under vacuum.
The material was dissolved in dry C6H6 (4ml) and the
resulting solution was added to cold ( 78 C) stirred
hexane (100ml). The pure deoxyribonucleoside phosphor-
amidite precipitated immediately as a yellowish solid.
After careful decantation of hexane, the solid was
dissolved in dry C6H6 (4ml); the solution was frozen
and then lyophilized under high vacuum. Et3N-free 27
was isolated as a yellowish powder (451mg, 640mmol,
92%).
31P NMR (121MHz, C6D6): d 148.1, 147.7.
+ESI-HRMS: Calcd for C37H42N5O7P (M+H)
+
700.2895, found 700.2904.
20-O-[2-(Methylthio)ethanimine-N-oxymethyl]uridine (28)
Commercial 2-methylthioacetaldehyde dimethylacetal was
converted in situ to methylthiomethylacetaldehyde under
conditions identical to those employed for the preparation
of N-(2-oxoethyl)biotinamide with the exception of the
reaction scale, which was 10-fold larger. The acidic
solution of methylthioacetaldehyde in aqueous methanol
was used without workup in the preparation of 28.2 0-O
(Aminooxymethyl)uridine (5a) was prepared from silica
gel-puriﬁed 4a at a scale of 2mmol under conditions
identical to those described for the preparation of 6a.
After complete NH4F-mediated desilylation and
dephthalimidation, all of the acidic methylthioace-
taldehyde solution prepared above was added to the
reaction mixture, which was heated at 55 C in a 4-ml
screw-cap glass vial until completion of the oximation
reaction (1h) as indicated by TLC [CHCl3:MeOH (9:1
v/v)]. The reaction mixture was puriﬁed by chromatog-
raphy on silica gel employing a gradient of MeOH (0 !
5%) in CH2Cl2 as the eluent. Fractions containing the
pure product were collected and evaporated to dryness
under reduced pressure providing 28 as a white powder
(557mg, 1.54mmol) in a yield of 77% based on the molar
amount of starting material (4a) that was utilized.
1H
NMR (300MHz, DMSO-d6): d 11.31 (br s, 1H), 7.87
(d, J=8.1Hz, 0.25H), 7.85 (d, J=8.1Hz, 0.75H), 7.34
(t, J=6.7Hz, 0.75H), 6.89 (t, J=6.0Hz, 0.25H), 5.90 (d,
J=5.9Hz, 0.75H), 5.88 (d, J=5.9Hz, 0.25H)), 5.66 (d,
J=8.1Hz, 0.75H), 5.65 (d, J=8.1Hz, 0.25H), 5.22-5.11
(m, 3H), 5.05 (d, J=7.8Hz, 1H), 4.25 (dt J=5.5, 5.3Hz,
1H), 4.13 (m, 1H), 3.87 (dt, J=3.3, 3.1Hz, 1H), 3.65-3.51
(m, 2H), 3.28 (ddd, J=6.4, 5.9, 5.7Hz, 1H), 3.11 (ddd,
J=6.9, 6.6, 6.5Hz, 1H), 2.01 (s, 0.75H), 1.96 (s, 2.25H).
13C NMR (75MHz, DMSO-d6): d 162.9, 150.4, 149.5,
149.0, 140.5, 101.9, 101.8, 95.7, 95.6, 85.9, 85.7, 85.3,
85.2, 78.7, 78.5, 68.7, 68.6, 60.8, 60.7, 30.9, 26.4, 14.6, 13.8.
50-O-(4,40-Dimethoxytrityl)-20-O-[2-
(methylsulﬁnyl)ethanimine-N-oxymethyl]uridine (29)
To a solution of 28 (500mg, 1.38mmol) in methanol
(20ml) was added 30% H2O2 (5ml). The solution was
allowed to stir at  25 C until completion of the reaction
(2h) as monitored by TLC [(CHCl3:MeOH (9:1 v/v)]. The
reaction mixture was evaporated to dryness under reduced
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on silica gel using a gradient of CH3OH (0!7%) in
CH2Cl2. Fractions containing the pure product were col-
lected and evaporated to a foam under low pressure. The
oxidized material was dried by co-evaporation with an-
hydrous pyridine (3 5ml) under reduced pressure. Dry
pyridine (10ml) was added and was followed by
4,40-dimethoxytrityl chloride (474mg, 1.40mmol). TLC
analysis [(CHCl3:MeOH (95:5 v/v)] of the reaction
showed a complete reaction within 16h at  25 C. The
reaction mixture was then poured into a saturated solution
of NaHCO3 (200ml) and was extracted with CH2Cl2
(3 150ml). The combined organic layers were dried
over anhydrous Na2SO4. Following ﬁltration, the ﬁltrate
was evaporated under reduced pressure and the material
left was puriﬁed by chromatography on silica gel using a
gradient of CH3OH (0!2%) in CH2Cl2 containing 0.2%
Et3N as the eluent. Fractions containing pure 29 were
collected and evaporated to a foam under low pressure.
The puriﬁed product was dissolved in dry C6H6 (10ml);
the resulting solution was frozen and was then lyophilized
under high vacuum to provide 29 as a powder (830mg,
1.22mmol, 89%). The stereochemical complexity of 29
precluded its facile characterization by NMR spectros-
copy. The ribonucleoside 29 was characterized as its
30-phosphoramidite derivative 30.
50-O-(4,4’-Dimethoxytrityl)-30-O-[(N,N-diisopropylamino)
(2-cyanoethyl)]phosphinyl-20-O-[2-
(methylsulﬁnyl)ethanimine-N-oxymethyl]uridine (30)
This compound was prepared from 29, puriﬁed and pro-
cessed under conditions similar to those described for the
preparation of the phosphoramidite 8a. The
phosphoramidite 30 was isolated as a white powder
(801mg, 0.91mmol, 83%).
31P NMR (121MHz, C6D6):
d 151.7, 151.6, 150.5, 150.1, 150.0. +ESI-HRMS: Calcd
for C43H54N5O11PS (M+Na)
+902.3170, found 902.3187.
General procedure for the removal of functional
groups from the ribonucleoside conjugates 6a–d,
12, 14, 16 and 18
Puriﬁed 6a (5.0mg, 10mmol) was placed in a 4-ml screw-
cap glass vial and 0.5M TBAF in THF (100ml) was
added. The tightly closed vial was heated at 55 C;
progress of the reaction was monitored by RP-HPLC.
Excess solvent was removed under a stream of air; the
material left was dissolved in HPLC buffer A (0.1M
triethylammonium acetate, pH 7.0, 500ml). An aliquot
(2ml) was analyzed by RP-HPLC according to the follow-
ing conditions: starting from 0.1M triethylammonium
acetate pH 7.0, a linear gradient of 1% MeCN/min was
pumped at a ﬂow rate of 1ml/min for 40min; the gradient
was then increased to 6% MeCN/min for 10min at the
same ﬂow rate and was kept isocratic for an additional
15min. Peak heights were normalized to the highest peak,
which was set to 1 AU.
Solid-phase synthesis of modiﬁed chimeric RNA sequences
The solid phase syntheses of 50-r(U*AUCCGUAGCUAA
CGUCAUG)dT (31) and 50-r(U*AUCCGUAGCU*AAC
GUCAUG)dT (32) [U* and dT correspond to 20-O-
(pyren-1-ylmethanimine-N-oxymethyl)uridine and 20-de-
oxythymidine residues, respectively] and 50-r(UAUCCG
UAGCUAACGUCAUG)dT (33) were conducted on a
scale of 0.2mmole in the ‘trityl-off’ mode using a
succinyl long chain alkylamine controlled-pore glass
(CPG) support functionalized with 20-deoxythymidine
as the leader nucleoside. The syntheses were carried out
using a DNA/RNA synthesizer and commercial 20-O-
(tert-butyldimethylsilyl) A
Pac,G
Pac,C
Ac and U phosphor-
amidite monomers (Pac and Ac correspond to
phenoxyacetyl and acetyl, respectively), which were dis-
solved in dry MeCN to give 0.15M solutions. The
pyrenylated ribonucleoside phosphoramidite 8a was also
used as a 0.15M solution in dry MeCN. 5-Benzylthio-1H-
tetrazole (0.25M in MeCN) and all other ancillary
reagents necessary for oligonucleotide synthesis were
obtained from commercial sources. The reaction time for
each phosphoramidite coupling step was set to 5min. The
dedimethoxytritylation, capping and oxidation steps of
any synthesis cycle were each performed over a period
of 60s.
Solid-phase synthesis of modiﬁed DNA sequences
The solid-phase syntheses of 50-d(T*ATCCGTAGCTAA
CGTCATGT) [T* corresponds to 50-O-(pyren-
1-ylmethanimine-N-oxymethyl)-20-deoxythymidine] (34)
and 50-d(TATCCGTAGCTAACGTCATGT) (35) were
carried out using the 50-pyrenylated deoxyribonucleoside
phosphoramidite 27 and commercial dA
Pac,d G
Pac,d C
Ac
and dT phosphoramidite monomers, as 0.1M solutions in
dry MeCN, under conditions identical to those employed
in the syntheses of 31–33 with the following exceptions: (i)
1 H-tetrazole (0.45M in MeCN) was used for
phosphoramidite activation; (ii) the reaction time for
each phosphoramidite coupling step was set to 3min
and; (iii) the dedimethoxytritylation, capping and oxida-
tion steps of any synthesis cycle were each performed over
a period of 60s, 30s and 30s, respectively.
Solid-phase synthesis of r(U20)dT (37) from the
phosphoramidite derivative of a reversible uridine
20-conjugate
The solid phase syntheses of r(U
+
20)dT (36)[ U
+ and dT
correspond to 20-O-[2-(methylsulﬁnyl)ethanimine-N-
oxymethyl]uridine and 20-deoxythymidine residues, respect-
ively] and the corresponding control sequence
r(U20)dT (37) were conducted using the 20-O-[2-(methylsul-
ﬁnyl)ethanimine-N-oxymethyl]uridine phosphoramidite 30
and commercial 20-O-(tert-butyldimethylsilyl)uridine
phosphoramidite monomers, respectively, as 0.2M solu-
tions in dry MeCN, under conditions identical to those
employed in the syntheses of 31–33 with the exception of
the coupling reaction time for phosphoramidite 30, which
was set to 3min.
Deprotection and characterization of the chimeric RNA
sequences
The solid-phase-linked 50-dedimethoxytritylated RNA
oligonucleotide (31, 32 or 33) was placed into a 4ml
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aqueous NH3 (1ml). The suspension was shaken occasion-
ally over a period of 30min at  25 C. The ammoniacal
solution was then transferred to another 4ml glass screw-
capped and was left standing at  25 C for 16h. A sample
of the ammoniacal solution (5 OD260) was evaporated to
dryness using a stream of air. The oligonucleotide was
then dissolved in DMSO (50ml) and Et3N 3HF (65ml)
was added to the solution, which was heated to for 2.5h
at 65  C. The solution was then concentrated under a
stream of air, diluted in 0.1M triethylammonium acetate
pH 7.0 and puriﬁed by RP-HPLC using a 5mm Supelcosil
LC-18S column (25cm 4.6mm) under the following
conditions: starting from 0.1M triethylammonium
acetate pH 7.0, a linear gradient of 1% MeCN/min was
pumped at a ﬂow rate of 1ml/min for 40min and was then
held, isocratically, for 20min. Fractions containing the
pyrenylated (31 or 32) or unmodiﬁed oligonucleotide
(33) were pooled together, concentrated to a volume of
 250ml and loaded onto a PD-10 (Sephadex G-25M)
column. The oligonucleotide was eluted from the column
using DEPC-treated H2O as the eluent. Fractions of 1ml
were collected and those containing the RNA oligomer
(A260) were pooled together for analysis by RP-HPLC
and characterization by mass spectrometry. –MALDI-
TOF MS (31): Calcd for C217H239N75O147P20 [M H]
+
6868, found 6868. –MALDI-TOF MS (32): Calcd for
C235H250N76O148P20 [M H]
+ 7125, found 7126.
–MALDI-TOF MS (33): Calcd for C199H228N74O146P20
[M H]
+ 6611, found 6611. Samples (1 OD260) of the
puriﬁed and desalted oligoribonucleotides 31 and 32
were evaporated to dryness using a stream of air and
were treated with 0.5M TBAF in DMSO (0.1ml) for 2h
at 55 C. Each solution was diluted using 0.1M
triethylammonium acetate pH 7.0 (1ml) and desalted as
described above through a PD-10 column prior to
RP-HPLC analysis and characterization by mass spec-
trometry. –MALDI-TOF MS (31!33): Calcd for
C199H228N74O146P20 [M H]
+ 6611, found 6613. –
MALDI-TOF MS (32!33): Calcd for
C199H228N74O146P20 [M H]
+ 6611, found 6611.
Deprotection and characterization of DNA sequences
The solid-phase-linked 50-dedimethoxytritylated 50-
pyrenylated oligodeoxyribonucleotide 34 or DNA oligo-
nucleotide 35 was placed into a 4ml screw-capped glass
vial to which was added concentrated aqueous NH3 (1ml).
The suspension was shaken occasionally over a period of
30min at  25 C. The ammoniacal solution was then
transferred to another 4ml glass screw-capped and was
left standing at  25 C for 16h. A sample of the ammoni-
acal solution (1 OD260) was evaporated to dryness using a
stream of air, redissolved in 0.1M triethylammonium
acetate pH 7.0 and puriﬁed by RP-HPLC under condi-
tions identical to those used for the puriﬁcation of 31–
33. The puriﬁed DNA sequences were desalted under con-
ditions identical to those used for the RNA sequences and
were analyzed by RP-HPLC (Supplementary Figure S7)
and characterized by mass spectrometry. –MALDI-TOF
MS (34): Calcd for C223H251N75O127P20 [M H]
+ 6632,
found 6633. –MALDI-TOF MS (35): Calcd for
C205H240N74O126P20 [M H]
+ 6375, found 6372.
A sample (1 OD260) of the puriﬁed and desalted
oligodeoxyribonucleotide 34 was evaporated to dryness
using a stream of air and was treated with 0.5M TBAF
in DMSO (0.1ml) for 1h at 55 C. After diluting the
solution with 0.1M triethylammonium acetate pH 7.0
(1ml), the solution was desalted as described above
through a PD-10 column prior to RP-HPLC analysis
(Supplementary Figure S7) and characterization by mass
spectrometry. –MALDI-TOF MS (34!35): Calcd for
C205H240N74O126P20 [M H]
+ 6375, found 6378.
Deprotection of r(U
+
20)dT (36) and characterization
of its conversion to r(U20)dT (37)
The solid-phase-linked 50-dedimethoxytritylated RNA
oligonucleotide 36 or 37 was placed into a 4ml screw-
capped glass vial to which was added concentrated
aqueous NH3 (1ml). The suspension was shaken occasion-
ally over a period of 30min at  25 C. The ammoniacal
solution was then transferred to another 4ml glass
screw-capped and was evaporated to dryness using a
stream of air. The oligonucleotide was then dissolved
with 0.5M TBAF in DMSO (0.1ml) and was heated for
16h at 55 C. After diluting the solution with 0.1M
triethylammonium acetate pH 7.0 (1ml), the solution
was desalted, as described above, through a PD-10
column prior to RP-HPLC analysis (Figure 6) and char-
acterization by mass spectrometry. –MALDI-TOF MS
(36!37): Calcd for C190H214N42O165P20 [M H]
+ 6344,
found 6349. –MALDI-TOF MS (37): Calcd for
C190H214N42O165P20 [M H]
+ 6344, found 6350.
RESULTS AND DISCUSSION
Synthesis and oximation of 20-O-aminooxymethyl
ribonucleosides
The preparation of the pyrenylated ribonucleosides 6a–d
from commercially available ribonucleosides (1a–d)i s
outlined in Scheme 1. The reaction of 1a–d with DMSO,
acetic anhydride and acetic acid produced the ribonucleo-
side 20-thioacetals 2a–d in yields of 85–94%; these acetals
were efﬁciently converted to their chloromethyl ether de-
rivatives (3a–d) by treatment with sulfuryl chloride (26,27)
in CH2Cl2 and were isolated, without puriﬁcation, as
amorphous materials. The addition of a pre-mixed solu-
tion of N-hydroxyphthalimide and a limiting amount of
DBU ( 0.9 molar equiv) in CH2Cl2 to 3a-d gave the 2’-O-
phthalimidooxymethyl ribonucleosides 4a–d in yields of
66–94% relative to the molar amounts of 2a–d that were
used as starting materials. Desilylation and, unexpectedly,
dephthalimidation of 4a–d occurred when treated with
a suspension of NH4F in MeOH (23), thereby affording
the novel 20-O-aminooxymethyl ribonucleosides 5a–d after
N-deacylation of the nucleobases upon exposure to
concentrated aqueous NH3. For characterization
purposes, analytical samples of 5a–d were puriﬁed by
silica gel chromatography and were analyzed by
1H and
13C NMR spectroscopies and high resolution mass spec-
trometry (HRMS). Otherwise, unpuriﬁed 5a–d was
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afforded the pyrenylated ribonucleoside conjugates 6a–d
in post-puriﬁcation yields of 69–82%; the identities of
6a–d were conﬁrmed by HRMS analysis. It should be
noted that partial deacylation of the nucleobases
occurred during the desilylation and dephthalimidation
of 4b–d. However, if required, N-acylation of the
nucleobases can be easily achieved by transient protection
of the hydroxyl functions of 6b–d by treatment with
chlorotrimethylsilane in dry pyridine followed by reac-
tion with the desired acylating reagent as described by
Ti et al. (28). It is also worth noting that when the
desilylation of 4a was effected by treatment with 0.5M
TBAF in THF, uridine was the only nucleosidic product
detected by RP-HPLC analysis of the deprotection
reaction. Similarly, when 4a was successively treated
with hydrazine hydrate to release the aminooxymethyl
function and with NH4F in methanol to desilylate the
50-and 30-hydroxy groups, RP-HPLC analysis of the reac-
tion revealed only uridine as the nucleosidic product.
Further investigations are necessary to fully assess the
mechanistic implications of these ﬁndings, which convin-
cingly underscore the uniqueness of the concomitant
desilylation and dephtalimidation of 4a–d by NH4Fi n
MeOH.
With the intent of further substantiating the versatility
of 4a–d in the preparation of ribonucleoside 20-conjugates,
the ribonucleoside 4a was converted to 20-O-aminooxy-
methyl uridine (5a), as described above, by treatment
with NH4F/MeOH, and was reacted with either
cholesten-3-one (9) or with aldehydes derived from N-
(2,2-dimethoxyethyl)biotinamide (11), N-(2,2-dimethoxy-
ethyl)-5-(dimethylamino)-naphthalene-1-sulfonamide (13)
and N-(4,4-diethoxybutyl)-5-(dimethylamino)naphthalene-
1-sulfonamide (15) to give the uridine 20-conjugates 10,
12, 14 and 16, respectively (Figure 1). The reaction of 20-
O-aminooxymethyl cytidine (5b) with the aldehyde
derived from N-(2,2-dimethoxyethyl)-4-(dimethylamino)-
azobenzene-40-sulfonamide (17) afforded the cytidine
20-conjugate 18 (Figure 1). The acetals 11, 13, 15 and 17
were conveniently prepared from the reaction of amino-
acetaldehyde dimethyl acetal or 4-aminobutyraldehyde
diethyl acetal with D-(+)-biotin 2-nitrophenyl ester,
dansyl chloride and dabsyl chloride in the presence of
triethylamine. These acetals were isolated in yields of
91–95%. The equilibrium between acetals 11, 13, 15 and
their corresponding aldehydes upon exposure to
concentrated HCl in MeOH led to efﬁcient conjugation
with 5a to provide the conjugates 12, 14 and 16 in
isolated yields of 66–81%. The acetal 17 did not signiﬁ-
cantly convert to the aldehyde under acidic conditions
presumably because protonation of the acetal’s azo
function might have considerably decreased its solubility
in MeOH. This shortcoming was avoided by the reaction
of 17 with a solution of 10% iodine in acetone as
described in the literature (24); under these conditions,
the crude N-(2-oxoethyl)-4-(dimethylamino)azobenzene-
40-sulfonamide was obtained and, without further puriﬁ-
cation, was reacted with the 20-O-aminooxymethyl
ribonucleoside 5b. The cytidine 20-conjugate 18 was
obtained in a yield exceeding 60%.
Reversibility of ribonucleoside 20-conjugates to their
ribonucleoside precursors
Ribonucleoside 20-conjugates 6a–d, 12, 14, 16 and 18 are
stable conjugates, which can be conveniently and efﬁcient-
ly converted to their native ribonucleoside precursors upon
treatment with 0.5M TBAF in THF. A proposed mech-
anism for these transformations is shown in Scheme 2 and
is supported by representative RP-HPLC proﬁles illustrat-
ing the conversion of 6a, 12 and 14 to uridine (Figure 2,
Supplementary Figures S2 and S3, respectively). The RP-
HPLC chromatograms demonstrate the formation of
pyrene-1-carbonitrile (19)a n dN-(4-cyanobut-1-yl)-5-
(dimethylamino)naphthalene-1-sulfonamide (20,F i g u r e3 )
as side products from the ﬂuoride-assisted cleavage of
the 20-iminooxymethyl ether function from 6a and 16, re-
spectively (Figure 2 and Supplementary Figure S4). The
identities of 19 and 20 were conﬁrmed by their RP-HPLC
retention times (tR=61.5 and 48.2min, respectively),
which were found identical to those of authentic commer-
cial (19) or chemically synthesized (20) samples (see
Figures 2 and 3, respectively). Although it had been
reported that the oxime phosphate ester 21 (Figure 3)
underwent base-catalyzed decomposition to produce
diphenyl phosphate and 4-nitrobenzonitrile (29), the
ﬂuoride-mediated cleavage of ribonucleoside 20-O-aryl or
-alkyliminooxymethyl ethers has not, to the best of our
knowledge, been reported in the literature.
It should be noted that the synthesis of 20-O-phthalimi-
dooxyethyl ribonucleosides had been reported earlier by
Kawasaki et al. (30) with the purpose of preparing 20-O-
aminooxyethyl-modiﬁed antisense oligonucleotides for
potential therapeutic applications. Although 20-O-
aminooxyethyl ribonucleosides can be amenable to conju-
gation with various functional groups, these permanent
conjugates cannot be easily converted back to unmodiﬁed
ribonucleosides.
In this regard, the reaction of the 20-O-aminooxymethyl
ribonucleoside 5a with cholesten-3-one (9) and dansyl
chloride also gave, as expected, the permanent uridine
20-conjugates 10 (Figure 1) and 22 (Figure 3), respectively.
These conjugates were both found stable to TBAF/
THF under the conditions used for the conversion
of 6a-d, 12, 14, 16 and 18 to their corresponding
ribonucleosides. Indeed, treatment of 22 with 0.5M
TBAF in THF for 72h at 55 C produced uridine to
the extent of <1%, as determined by RP-HPLC
analysis of the reaction products (data shown in
Supplementary Figure S6).
The conjugates 6a–d, 12, 14, 16 and 18 exist as a mixture
of E- and Z-geometrical isomers; one of these isomers
appears to undergo ﬂuoride-assisted cleavage of the
20-iminooxymethyl ether function at a faster rate than
the other geometrical isomer, as judged by RP-HPLC
analysis of the cleavage reactions. Our ﬁndings are con-
sistent with those reported earlier by others (31) indicating
that both syn- and anti-piperonaldoxime acetates
produced a nitrile via b-elimination under basic condi-
tions; the trans-b-elimination from the anti-acetate pro-
ceeding faster than the cis-b-elimination. It is also worth
noting that the proximity of an electron-donating group to
Nucleic Acids Research,2012, Vol.40, No. 5 2323the 20-iminooxymethyl ether function clearly affects the
rates of the ﬂuoride-assisted cleavage reaction. As shown
in Figure 2, the ﬂuoride-mediated conversion of 6a to
uridine was complete within 4h at 55 C while the conver-
sion of 12 to uridine took 6h under identical conditions
(Supplementary Figure S2). One might argue that in the
presence of ﬂuoride ion, which is a strong base in aprotic
solvent, the amide function of 12 (pKa  25) may become
negatively charged to some extent and decrease the acidity
of the nearby oximic proton as a consequence of the
electron-donating properties of the partially ionized
amide function. The reduced acidity of the oximic
proton would then result in a slower ﬂuoride-mediated
b-elimination reaction. This argument is further supported
by the considerably slower ﬂuoride-assisted conversion of
14 to uridine, which was only 15% complete after 24h at
55 C (Supplementary Figure S3). The relatively acidic sul-
fonamide function of 14 (pKa  10) is presumably ionized
to a larger extent than that of an amide function by the
strongly basic ﬂuoride ion, thereby decreasing further the
acidity of the oximic proton, which led to slower
b-elimination rates relative to those of 6a–d and 12
under identical conditions. Also consistent with this
argument is that when the sulfonamide function is increas-
ingly distal to the oximic proton, the electron-donating
properties of the ionized sulfonamide have a lesser effect
on the acidity of the oximic proton and result in relatively
faster b-elimination rates. Typically, the ﬂuoride-assisted
Figure 1. Ribonucleoside 20-conjugates produced from the reaction of 5a or 5b with cholesten-3-one (9) or with aldehydes derived from various
acetals (11, 13, 15 and 17).
2324 Nucleic Acids Research, 2012,Vol.40, No. 5conversion of 16 to uridine was complete within 48h
at 55 C (Supplementary Figure S4); this b-elimination
rate is comparatively faster than that of 14 but still signiﬁ-
cantly slower than those of 6a–d and 12. Given the struc-
tural similarity of 18 and 14 in terms of proximity of the
sulfonamide function to the oximic proton, the conversion
of 18 to cytidine by treatment with 0.5M TBAF in
THF was comparable to that of 14 to uridine, as it was
only 25% complete after 24h at 55 C (Supplementary
Figure S5).
Single or double incorporation of a reversible
ribonucleoside 2’-conjugate into chimeric RNA sequences:
synthesis, deprotection and characterization
With the objective of demonstrating the ability of 20-O-
aminooxymethyl ribonucleoside conjugates to modify
RNA sequences, the pyrenylated ribonucleoside conjugate
6a was reacted with 4,40-dimethoxytrityl chloride in pyri-
dine to provide 7a, which after puriﬁcation, was reacted
with 2-cyanoethyl N,N-diisopropylchlorophosphor-
amidite and triethylamine to give the pyrenylated ribo-
nucleoside phosphoramidite 8a (Scheme 1). The RNA
sequences 50-r(U*AUCCGUAGCUAACGUCAUG)dT
(31), 50-r(U*AUCCGUAGCU*AACGUCAUG)dT (32)
[U* and dT correspond to 20-O-(pyren-1-ylmethanimine-
N-oxymethyl)uridine and 2’-deoxythymidine residues, re-
spectively] and 5’-r(UAUCCGUAGCUAACGUCA
UG)dT (33) were prepared using solid-phase techniques
(32) to show that the single or double incorporation of
pyrenylated ribonucleoside phosphoramidite 8a into
RNA sequences constructed from commercial 20-O-(tert-
butyldimethylsilyl) ribonucleoside phosphoramidites
(Supplementary ‘Materials and Methods’ section) pro-
ceeded without compromising the overall yields of the
RNA sequences on the basis of the stepwise colorimetric
determination of the dimethoxytrityl cation concentration
after the ﬁrst and last coupling steps of each oligonucleo-
tide assembly. Treatment of the solid-phase-linked oligo-
nucleotides with concentrated aqueous NH3 at ambient
temperature ( 25 C) resulted in the cleavage of all
nucleobase and phosphate protecting groups with the
release of the 20-O-protected oligonucleotides from the
CPG support. Exposure of 20-O-protected oligonucleo-
tides to Et3N 3HF (33,34) in DMSO at 65 C resulted in
the exclusive cleavage of the 20-O-TBDMS protecting
groups. Although the 20-O-pyrenylated ribonucleoside
conjugates 6a–d are cleaved by TBAF, these conjugates
are totally stable to Et3N 3HF under the conditions
used for complete cleavage of the 20-O-TBDMS groups.
The RP-HPLC retention times of the puriﬁed
Figure 2. RP-HPLC analysis of the ﬂuoride-assisted conversion of
silica gel-puriﬁed 20-O-(pyren-1-ylmethanimine-N-oxymethyl)uridine
(6a) to uridine. (A) Chromatogram of the silica gel puriﬁed 6a.( B)
Chromatogram of the conversion of 6a to uridine by treatment with
0.5M tetra-n-butylammonium ﬂuoride in THF for 3h at 55 C. (C)
Chromatogram of mixed uridine and pyrene-1-carbonitrile commercial
samples. Conditions: RP-HPLC analysis was performed using UV de-
tection (254nm) and a 5mm Supelcosil LC-18S column
(25cm 4.6mm) according to the following conditions: starting from
0.1M triethylammonium acetate pH 7.0, a linear gradient of 1%
MeCN/min was pumped at a ﬂow rate of 1ml/min for 40min; the
gradient was then increased to 6% MeCN/min for 10min at the
same ﬂow rate and kept isocratic for an additional 15min. Peak
heights are normalized to the highest peak, which is set to 1 AU.
Scheme 2. Fluoride-assisted conversion of 20-O-pyrenylated
ribonucleosides (6a–d) to native ribonucleosides. TBAF, tetra-n-
butylammonium ﬂuoride; B, uracil-1-yl, cytosin-1-yl, adenin-9-yl, or
guanin-9-yl.
Figure 3. Structures of compounds 20, 21 and 22.
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17.6min, respectively) were compared and found consist-
ent with the composition of each oligonucleotide under
identical chromatographic conditions (Figures 4 and 5).
MALDI-TOF analyses of 31, 32 and 33 corroborated
their expected molecular weights. The reversibility of the
20-O-pyrenylated oligonucleotides 31 and 32 to 33 was
demonstrated by the reaction of 31 and 32 with 0.5M
TBAF in DMSO at 55 C. Under these conditions, 31
and 32 were completely converted to 33, as shown by
RP-HPLC (Figures 4 and 5) and mass spectrometry
analyses of the fully deprotected oligonucleotides.
Functionalization of the 50-terminus of a DNA sequence
with a reversible conjugate: synthesis, deprotection and
characterization
It was also our intent to show that 50-O-aminooxymethyl
deoxyribonucleosides are similar to 20-O-aminooxymethyl
ribonucleosides in their abilities to produce conjugates
for the functionalization of DNA sequences at their
50-termini; 50-O-aminooxymethyl thymidine (25) served
as an appropriate model for this purpose. The synthesis
of 25 (Scheme 3) began with the thioacetalization of com-
mercial 30-O-levulinyl thymidine under conditions similar
to those used for the 20-O-thioacetalization of 1a–d. The
50-O-thioacetal 23 was then treated with sulfuryl chloride
to yield the 50-chloromethylated deoxyribonucleoside
intermediate, which was reacted with N-hydroxyphthalimide
in the presence of DBU to provide 24. Hydrazinolysis of 24
resulted in the cleavage of the phthalimido and levulinyl
groups affording 50-O-aminooxylmethyl thymidine (25).
Oximation of 25 with pyrenecarboxaldehyde in MeOH at
55 C led to the 50-pyrenylated thymidine derivative 26,
which was puriﬁed and phosphitylated using 2-cyanoethyl
N,N-diisopropylchlorophosphoramidite and triethylamine
under anhydrous conditions to give the 50-pyrenylated
thymidine phosphoramidite 27. The DNA sequences
50-d(T*ATCCGTAGCTAACGTCATGT) (34) [T* cor-
responds to 50-O-(pyren-1-ylmethanimine-N-oxymethyl)-
20-deoxythymidine] and 50-d(TATCCGTAGCTAACGT
CATGT) (35) were synthesized, using the phosphor-
amidite 27 and commercial dA
Pac,d G
Pac,d C
Ac and dT
phosphoramidite monomers under the conditions de-
scribed in the experimental section. Post-synthesis oligo-
nucleotide deprotection was carried out by treatment with
concentrated aqueous NH3 at  25 C. The coupling efﬁ-
ciency of 27 was found comparable to that of commercial
deoxyribonucleoside phosphoramidites given the similar
recovery of both 34 and 35, as judged by UV spectroscopy
at 260nm. The 50-pyrenylated DNA sequence 34 ex-
hibited, as expected, a retention time (tR=33.4min) con-
siderably larger than that of the control DNA sequence 35
(tR=18.2min) as a consequence of the notorious hydro-
phobicity of the pyrenyl function. (Supplementary
Figure S7). The identity of both 34 and 35 was conﬁrmed
by mass spectrometry. The reversibility of the 50-pyreny-
lated DNA sequence 34 was also veriﬁed by its reaction
with 0.5M TBAF in DMSO at 55 C. Under these condi-
tions 34 was completely converted to 35 on the basis of
Figure 4. RP-HPLC analysis of puriﬁed and desalted
50-r(U*AUCCGUAGCUAACGUCAUG)dT (31) [U* and dT repre-
sent 20-O-(pyren-1-ylmethanimine-N-oxymethyl)uridine and
20-deoxythymidine residues, respectively] and its conversion to
50-r(UAUCCGUAGCUAACGUCAUG)dT (33). (A) Chromatogram
of 31 that was prepared from the 20-O-pyrenylated ribonucleoside
phosphoramidite 8a and commercial 20-O-(tert-butyldimethylsilyl)
A
Pac,G
Pac,C
Ac and U phosphoramidite monomers, deprotected,
RP-HPLC puriﬁed and desalted as delineated in the ‘Materials and
Methods’ section. (B) Chromatogram of 33 that was prepared from
commercial 20-O-(tert-butyldimethylsilyl) A
Pac,G
Pac,C
Ac and U
phosphoramidite monomers, and processed as described in (A). (C)
Chromatogram of RP-HPLC puriﬁed and desalted 31 that was
treated with 0.5M TBAF in DMSO for 2h at 55 C and then
desalted. RP-HPLC analysis was performed using UV detection
(254nm) and a 5mm Supelcosil LC-18S column (25cm 4.6mm) ac-
cording to the following conditions: starting from 0.1M
triethylammonium acetate pH 7.0, a linear gradient of 1% MeCN/
min was pumped at a ﬂow rate of 1ml/min for 40min and was then
held, isocratically, for 20min. Peak heights are normalized to the
highest peak, which is set to 1 AU.
Figure 5. RP-HPLC analysis of puriﬁed and desalted
50-r(U*AUCCGUAGCU*AACGUCAUG)dT (32) [U* and dT repre-
sent 20-O-(pyren-1-ylmethanimine-N-oxymethyl)uridine and
20-deoxythymidine residues, respectively] and its conversion to
50-r(UAUCCGUAGCUAACGUCAUG)dT (33). (A) Chromatogram
of 32 that was prepared from the 20-O-pyrenylated ribonucleoside
phosphoramidite 8a and commercial 20-O-(tert-butyldimethylsilyl)
A
Pac,G
Pac,C
Ac and U phosphoramidite monomers, deprotected,
RP-HPLC puriﬁed and desalted as delineated in the ‘Materials and
Methods’ section. (B) Chromatogram of 33 that was prepared from
commercial 20-O-(tert-butyldimethylsilyl) A
Pac,G
Pac,C
Ac and U
phosphoramidite monomers, and processed as described in (A). (C)
Chromatogram of RP-HPLC puriﬁed and desalted 32 that was
treated with 0.5M TBAF in DMSO for 2h at 55 C and then
desalted. RP-HPLC analysis was performed as described in the
caption of Figure 4.
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trometry analyses.
Reversible ribonucleoside 20-conjugate in the synthesis of
native RNA sequences: synthesis and characterization of
the chimeric polyuridylic acid model r(U20)dT
Given the pressing need for RNA sequences in RNA inter-
ference research (21), the versatility of reversible 20-O-
aminooxymethyl ribonucleoside conjugates in the design
of novel 20-hydroxyl protecting groups for the synthesis of
native or modiﬁed RNA sequences is clearly an asset. The
reaction of aldehydes or aldehydes derived from acetals
with 20-O-aminooxymethyl ribonucleosides was per-
formed with the purpose of assessing the stability of the
resulting 20-conjugates to the conditions prevailing during
the synthesis and deprotection of RNA sequences, and
evaluating the reversibility kinetics of these conjugates
when exposed to TBAF in DMSO. In preliminary experi-
ments, the 20-O-aminooxymethyl ribonucleoside inter-
mediate 5a was reacted with either acetaldehyde or
methythioacetaldehyde, the latter of which was produced
in situ from its commercial dimethyl acetal under acidic
conditions, to generate the expected oxime conjugates
(Scheme 4). Both ribonucleoside 20-conjugates were
found stable to the reagents and conditions used for
routine solid-phase RNA synthesis and to the mild basic
conditions that are required for N-deacylation of the
nucleobases, cleavage of the 2-cyanoethyl phosphate pro-
tecting groups and release of the 20-O-protected RNA
sequence from the CPG support. The conversion of 20-
O-[2-(methylthio)ethanimine-N-oxymethyl]uridine (28)t o
uridine upon exposure to 0.5M TBAF in DMSO was
complete within 30min at 55 C and was the fastest of
the two 20-O-aminooxymethyl ribonucleoside conjugates
investigated. In order to further improve the ﬂuoride-
assisted conversion of 28 to uridine, we rationalized that
by increasing the acidity of the oximic proton, the revers-
ibility of 28 to uridine should be enhanced. Indeed,
reaction of the sulfoxide derivative of 28 with 0.5M
TBAF in DMSO led to its complete transformation to
uridine within 5min at 25 C. These encouraging results
prompted us to prepare the ribonucleoside phosphor-
amidite 30, which was obtained from the
Scheme 3. Preparation of the pyrenylated deoxyribonucleoside
phosphoramidite 27. (i) DMSO, Ac2O, AcOH, 50 C, 16h; (ii) silica gel
chromatography; (iii) SO2Cl2,C H 2Cl2,2 5  C, 2h; (iv) N-hydroxy-
phthalimide, DBU, CH2Cl2,2 5  C, 24h; (v) 1M hydrazine hydrate in
pyridine:AcOH (3:2 v/v), 25 C, 1h; (vi) 1-pyrenecarboxaldehyde,
MeOH, 55 C, 1h; (vii) 2-cyanoethyl N,N-diisopropylchloropho-
sphoramidite, Et3N, CH2Cl2,2 5  C, 2h. Lev, levulinyl; Thy,
thymin-1-yl.
Scheme 4. Preparation of the ribonucleoside phosphoramidite 30.
(i) NH4F, MeOH, 25 C, 16h; (ii) methylthioacetaldehyde, MeOH,
55 C, 1h; (iii) silica gel chromatography; (iv) 30% H2O2, MeOH,
25 C, 2h; (v) DMTrCl, pyridine, 25 C, 16h; (vi) 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite, Et3N, CH2Cl2,2 5  C, 2h. Ura,
uracil-1-yl.
Nucleic Acids Research,2012, Vol.40, No. 5 232750-dimethoxytritylation of the sulfoxide derivative of 28 to
29 and its subsequent 30-phosphitylation by 2-cyanoethyl
N,N-diisopropylchlorophosphoramidite under the condi-
tions described in the caption of Scheme 4. The
ribonucleoside phosphoramidite 30 was successfully used
in the solid-phase synthesis of r(U
+
20)dT bearing the 2-
(methylsulﬁnyl)ethanimine-N-oxymethyl group for
20-hydroxyl protection. The iterative coupling efﬁciency
of 30 exceeded 99% and the yield of r(U
+
20)dT was
80±5% as determined by the colorimetric trityl assay.
Upon phosphate deprotection and release of r(U
+
20)dT
from the CPG support effected by aqueous NH3, the
ﬂuoride-mediated cleavage of the 20-O-[2-(methylsulﬁny-
l)ethanimine-N-oxymethyl] groups was subsequently per-
formed under anhydrous conditions by treatment with
0.5M TBAF in DMSO over a period of 16h at 55 C.
Unpuriﬁed r(U20)dT (37) was desalted, analyzed by
RP-HPLC and successfully characterized by MALDI-
TOF mass spectrometry. The RP-HPLC proﬁle of the
chimeric polyuridylic acid was compared with the proﬁle
of r(U20)dT that was prepared from commercial 20-O-
(tert-butyldimethylsilyl)uridine phosphoramidite mono-
mers and deprotected under standard conditions (32).
Figure 6 shows the high similarity of these chromato-
graphic proﬁles and strongly suggests that reversible
20-O-aminooxymethyl ribonucleoside conjugates may
lead to the development of novel 20-hydroxyl protecting
groups for the optimal preparation of native or modiﬁed
RNA sequences.
CONCLUSIONS
The synthesis of novel 20-O-aminooxymethyl ribonucleo-
sides (5a–d) provides facile access to reversible or perman-
ent ribonucleoside 20-conjugates through an efﬁcient and
chemoselective oximation reaction with aldehydes or
ketones. The synthetic process, whereby 20-O-phthalimi-
dooxymethyl ribonucleoside derivatives (4a–d) have gen-
erally been prepared from commercial ribonucleoside
precursors (1a–d) in relatively high yields is remarkable
in terms of simplicity; a unique feature of this process is
the one-step removal of the silyl and phthalimido groups
from 4a–d by treatment with methanolic ammonium
ﬂuoride. The reaction of 5a–d with 1-pyrenecarbox-
aldehyde or 5a with aldehydes, generated from acetals
(11, 13 and 15) under acidic conditions, gave stable but
reversible ribonucleoside 20-conjugates, whereas the
reaction of 5a with the cholestenone 9 or dansyl chloride
afforded permanent ribonucleoside conjugates. The con-
jugation of cholesterol derivatives to antisense oligo-
nucleotides has been reported to enhance the cellular
uptake and antisense efﬁcacy of these biomolecules in
cell-based systems (35). In this context, it has become ap-
parent that 20-O-aminooxymethyl ribonucleosides (5a–d)
are capable of forming conjugates with a variety of func-
tional groups. Conversion of these ribonucleoside conju-
gates, after 50-O- and nucleobase protection, to
30-phosphoramidite derivatives should permit their in-
corporation into oligonucleotides. These oligonucleotide
conjugates may particularly be useful in the development
of innovative approaches to improving the cellular uptake
of nucleic acid-based drugs through speciﬁc pathways.
Cellular uptake and localization of therapeutic oligo-
nucleotides are still the most challenging problems to
overcome in order to better control gene expression. In
addition, one of the important ﬁndings of this work is
the facile reversibility of ribonucleoside 20-conjugates to
native ribonucleosides upon treatment with 0.5M TBAF
in DMSO. As discussed above, TBAF induced the
b-elimination of 20-iminooxymethyl ether functions
through the formation of innocuous nitriles and thus
provides new opportunities for the discovery and imple-
mentation of novel 20-hydroxy protecting groups, which
are of crucial importance in the synthesis of native and/or
modiﬁed RNA sequences for RNA interference applica-
tions (21). Furthermore, the reversibility of DNA/RNA
oligonucleotides conjugated to speciﬁc ligands is particu-
larly useful in the afﬁnity puriﬁcation of synthetic DNA/
RNA from which intact DNA/RNA oligonucleotides can
be recovered from the ligand-afﬁnity binding system (36).
This approach may ﬁnd application in the large-scale syn-
thesis and puriﬁcation of therapeutic DNA/RNA
sequences. The reversibility of DNA/RNA oligonucleo-
tides conjugated to afﬁnity ligands may have a much
broader appeal when the reversible DNA/RNA conjugate
serves as an aptamer for capturing proteins from cell
lysates. This strategy may permit the identiﬁcation and
characterization of biomedically relevant DNA/RNA
protein complex(es) upon release from the ligand-afﬁnity
binding system.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Materials and Methods, and
Supplementary Figures S1–S7.
Figure 6. RP-HPLC analysis of the conversion of unpuriﬁed and
desalted 50-r(U
+
20)dT) [U
+ represents 20-O-[2-(methylsulﬁny-
l)ethanimine-N-oxymethyl]uridine] (36)t o5 0-r(U20)dT (37). (A)
Chromatogram of r(U20)dT 37 that was prepared from commercial
20-O-(tert-butyldimethylsilyl)uridine phosphoramidite, deprotected, and
desalted as delineated in the ‘Materials and Methods’ section. (B)
Chromatogram of 36 that was prepared from the ribonucleoside
phosphoramidite monomer 30 and processed as described in (A).
RP-HPLC analysis was performed as described in the caption of
Figure 4.
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